Thus, it is possible that Vδ1−Vδ2−Vγ9− cells producing cytokines other than IFN-γ and IL-17 are associated with protection against MS by immunomodulatory effects in IFN-β-treated patients. The gene discussed is IFNG; the disease is myeloid sarcoma.